Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent intermediate-grade or high-grade non-Hodgkin's lymphoma or mantle cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Alvocidib

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma with clinical or pathological evidence of recurrent disease

• Measurable or evaluable disease

• CNS metastases not requiring intravenous steroid therapy allowed

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: CALGB 0-2

• Life expectancy: At least 12 weeks

• Absolute neutrophil count at least 1500/mm3 (unless due to bone marrow involvement by lymphoma)

• Platelet count at least 100,000/mm3 (unless due to bone marrow involvement by lymphoma)

• At least 7 days since platelet transfusion

• Hemoglobin at least 9.0 g/dL

• Bilirubin no greater than 1.5 mg/dL

• Transaminases no greater than 2.5 times upper limit of normal

• Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min

• No significant uncontrolled medical or psychiatric illness

• No active serious infection

• Not pregnant or lactating

• Fertile patients must use effective contraception

• Central venous catheter required prior to study entry

PRIOR CONCURRENT THERAPY:

• No more than 1 prior chemotherapy regimen

• At least 4 weeks since prior chemotherapy and recovered from all toxic effects Prior chemotherapy must contain anthracycline if intermediate or high-grade NHL other than mantle cell

• No concurrent treatment with other chemotherapeutic or investigational antineoplastic drugs

• At least 4 weeks since prior radiation therapy and recovered (Site of only measurable disease must not be located within prior radiation therapy port)

• No concurrent radiation therapy to any lesion